In terms of the comments the member makes about funding some drugs for some indications and not others, that is one of the challenges that we've got, and that's one of the issues that Pharmac is going through right now with the additional funding that they've got, particularly in the cancer space. We know that Keytruda is a classic example. It's funded for some indications but not for others, but we know that it's efficacious for other indications. So that's one of the assessments they've been going through right now, to make sure that we are up to speed. If I go back to the work that the Cancer Control Agency did under the leadership of Professor Di Sarfati, who now turns out to be the Acting Director-General of Health, the work that was done on the gap between cancer treatments here and likeminded countries, particularly Australia, Canada, and the UK, showed that we've got a gap that we need to fill, and I'm confident that Pharmac is focused on that.